Tango Therapeutics Inc. vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $422.9 (market cap $2.02T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 538.7× Tango Therapeutics Inc.'s market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days on average.
| TNGX | TSM | |
|---|---|---|
Market Cap | $3.75B | $2.02T |
Volume | 9,619,106 | 8,566,236 |
Sector | Health | Technology |
52-Week High | $32.90 | $485.80 |
52-Week Low | $7.50 | $275.06 |
Typical Hold Time | 0 Days | 111 Days |
Enterprise Value | $2.77B | $1.94T |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
TSMC (TSM) trades at $445.12, up 0.17% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue and net income have shown robust growth, with 2025 revenue at $3.81T and net income at $1.70T. Analyst sentiment is overwhelmingly positive, with a consensus price target of $578.43, representing significant upside. Recent news highlights TSMC's pivotal role in AI chip manufacturing and upcoming dividend payments.
The outlook for TSM is favorable, driven by strong earnings momentum, high profitability margins, and its dominant position in semiconductor manufacturing. Key opportunities include continued AI-driven demand and technological leadership. Risks involve geopolitical tensions, competitive pressures, and market volatility. The stock presents a compelling long-term investment case supported by analyst optimism and solid financial health.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →